Ispitivanje serološkog statusa na Epštajn-Bar virus u odrasloj populaciji
Sažetak
Uvod: Epštajn-Bar virus (EBV) je ubikvitarni virus iz familije Herpesviridae, seroprevalencije ˃90% svetske populacije. Primarna infekcija prolazi kao asimptomatska ili u obliku infektivne mononukleoze, zavisno od uzrasta i imunološkog statusa pojedinca. Virus uspostavlja latentnu infekciju u B limfocitima sa povremenom reaktivacijom, a zbog svog onkogenog potencijala asociran je sa pojavom brojnih maligniteta. Podaci o EBV seroprevalenciji u populaciji zdravih odraslih osoba iz Srbije su oskudni.
Cilj: Ispitivanje serološkog statusa na EBV u odrasloj populaciji dokazivanjem specifičnih antitela na antigene virusa.
Materijal i metode: Uzorci seruma 58 ispitanika (starost: 30,8±13,7 godina; pol: M=41,4%, Ž=58,6%), testirani su pomoću komercijalnih ELISA testova na prisustvo četiri antitela protiv EBV (anti-VCA-IgM, anti-VCA-IgG, anti-EA-IgG i anti-EBNA-IgG). Na osnovu preporuka iz literature, svaki ispitanik je u zavisnosti od rezultata serološkog testa, svrstan u odgovarajući profil EBV infekcije (primarna, latentna, reaktivacija).
Rezultati: U 89,5% uzoraka seruma naših ispitanika dokazana su antitela protiv EBV sa trendom porasta procenta seropozitivnih sa godinama starosti: od 87% seropozitivnih u populaciji 18-30 godina, do 100% u starijem delu populacije. Profil latentne infekcije je imalo 81% ispitanika, 3,4% ispitanika profil primarne infekcije, 3,4% profil reaktivirane infekcije, a 1,7% neodređeni profil. Nije pronađena statistički značajna razlika (p˃0,05) između titra anti-VCA-IgG niti anti-EBNA-IgG antitela u različitim starosnim grupama, kao ni između polova. Takođe, nije pronađena značajna razlika (p˃0,05) ni između broja EBV seropozitivnih osoba među polovima, niti među starosnim grupama.
Zaključak: Naše istraživanje je pokazalo visoku stopu latentne EBV infekcije, od 81%, što ukazuje na visok stepen prokuženosti ispitivane populacije ovim virusom. Razlike seroprevalencjii između polova nisu pronađene, kao ni između različitih starosnih grupa. Dalje istraživanje EBV seroprevalencije u našoj populaciji potrebno je zbog praćenja broja reaktiviranih infekcija, asocijacije sa razvojem malignih bolesti kao i zbog potencijalnog razvoja i primene vakcine protiv EBV.
Ključne reči: Epštajn-Bar virus; seroprevalencija; latencija; anti-EBV antitela
Reference
2. Keiji I, Takenobu Y, Kazuhide T, Daisuke S, Kazuyasu F, Hironori M, et al. A Spectrum of Clinical Manifestations Caused by Host Immune Responeses against Epstein-Barr Virus Infections. Acta.med. Okayama. 2004; 58(4):169-180.
3. Odumade OA, Hogquist KA, Balfour HH. Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections. Clinical Microbiology Reviews. 2011; 24(1):193-209.
4. Tempera I, Lieberman P. Epigenetic regulation of EBV Persistence and Oncogenesis. Semin Cancer biol. 2014; 0:22-29.
5. Smatti MK, Al-Sadeq DW, Ali NH, Pintus G, Abou-Saleh H, Nasrallah GK. Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. Frontiers in Oncology. 2018; 8(211).
6. Figuera-Silva CM, Pereira FE. Prevalence of Epstein-Barr virus antibodies in healthy children and adolescents in Vitoria, State of Espirito Santo, Brazil. Revista da Sociedade Brasileira de Medicina Tropical. 2004; 37(5):409-412.
7. Balfour HH, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-Specific Prevalence of Epstein –Barr Virus Infection Among Individuals Aged 6-19 Years in the Unites States and Factors Affecting Its Acquisition. The Journal of Infectious Diseases. 2013; 208(8).
8. Brkić S, Jovanović J, Preveden T, Vukobratov Z. Serološki profil Epstein-Barr virusne infekcije u akutnoj infektivnoj mononukleozi. Med Pregl. 2003; 56(1-2):7-16.
9. Lindsey JW, Hatfield LM, Vu T. Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis. Eur J Neurol. 2010; 17(10):1263-1269.
10. Draborg AH, Jergensen JM, Muller H, Nielsen CT, Jacobsen S, Iversen LV, et al. Epstein-Barr virus early antigen diffuse (EBV-EA/D)-direct immunoglobulin A antibodies in systematic lupus erythematosus patients. Scand J Rheumatol. 2012; 41:280-289.
11. Jiang Y, Zilioli S, Stowe R, Rubinstein R, Peek K, Cutchin M. Perceived social support and latent herpesvirus reactivation: Testing main and stress-buffering effects in an ethnically diverse sample od adults. Psychosom Med. 2021; 83(7):767-776.
12. Smatti MK, Yassine HM, AbuOdeh R, AlMarawani A, Taleb SA, Althani A, et al. Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. PloS ONE. 2017; 12(12): e0189033.
13. Eksi F, Karsligil T, Erinmez M, Pehlivan M. Investigation of Epstein-Barr Virus antibodies by ELISA and IFA methods. J Exp Clin Med. 2022; 39(1):66-70.
14. Sharifipour S, Rad KD. Seroprevalence of Epstein-Barr virus among children and adults in Tehran, Iran. New Microbes and New Infections. 2020; 34(C).
15. Adjei AA, Armah HB, Gbagbo F, Boamah I, Adu-Gyamfi C, Asare I. Seroprevalence of HHV-8, CMV and EBV among thr general population in Ghana, West Africa. BMC Infectious diseases. 2008; 8:111.
16. Wnter JR, Taylor GS, Thomas OG, Jackson C, Lewis JEA, Stagg HR. Predictors of Epstein-Barr virus serostatus in young people in England. BMC Infectious diseases. 2019; 1007.
17. Klutts JS, Ford BA, Perez NR, Gronowski AM. Evidence-Based Approach for Interpretation of Epstein-Barr Virus Serological Patterns. Journal of Clinical Microbiology. 2009; 3204-3210.
18. Freitas LF, Silva JM, Barbosa AN, Pinheiro-Silva R, Pontes GS. Epidemiological and Liver Biomarkers Profile of Epstein-Barr Virus Infection and Its Coinfection with Cytomegalovirus in Patients with Hematological Diseases. Biomolecules. 2021; 11:1151..
19. Abrahamyan S, Eberspaccher B, Hoshi M-M, Aly L, Luessi F, Groppa S et al. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020; 91:681-686.
20. Wood RA, Guthridge L, Turmond E, Guthridge CJ, Kheir JM, Bourn RL et al. Serologic markers of Epstein-Barr virus reactivation with increased disease activity, inflammation, and interferon pathway activation in patients with systematic lupus erythomatosus. Journal of translational autoimmunity. 2021; 4:100117.
21. Sausen DG, Bhutta MD, Gallo ES, Dahari H, Borenstein R. Stress-Induced Epstein-Barr Virus Reactivation. Biomolecules. 2021; 11:1380.
22. Balfour HH, Meirhaeghe MR, Stancari A, Geris JM, Condon L, Cederberg LE. Declining Epstein-Barr Virus Antibody prevalence in College Freshmen Strengthens the Rationale for a Profilactic EBV Vaccine. Vaccines. 2022; 10:1399.
23. Fourcade G, Germi R, Guerber F, Lupo J, Baccard M, Seigneurin A et al. Evolution of EBV seroprevalence and primary infection age in French hospital and city laboratory network 2000-2016. PloS ONE. 2017; 12(4):e0175574.
24. Beader N, Kolarić B, Slačanac D, Tabain I, Vilibić-Čavlek T. Seroepidemiological Study of Epstein-Barr Virus in Different Population Groups in Croatia. IMAJ. 2018; 20.